Groupe D'etude Therapeutique Des Affections Inflammatoires Digestives

This study tests whether increasing the dose of guselkumab can help people with Crohn's disease who don't get better with standard doses. About 210 adults with active Crohn's will receive guselkumab, and after 12 weeks, those who haven't responded will get a higher dose more ofte…

This study tests if the drug mirikizumab can heal damage deep in the gut wall in people with Crohn's disease. About 75 adults with active symptoms and inflammation seen on MRI will receive the drug. The main goal is to see if the gut shows at least 25% improvement after 24 weeks.

This study is testing whether a remote monitoring app can help people with active inflammatory bowel disease (Crohn's or ulcerative colitis) spend more time in remission. About 290 adults whose disease is flaring will use the app to track symptoms and health data. The goal is to …